Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Contineum Therapeutics (CTNM) EBIT Margin (2023)

Historic EBIT Margin for Contineum Therapeutics (CTNM) over the last 1 years, with Q2 2023 value amounting to 77.87%.

  • Contineum Therapeutics' EBIT Margin changed N/A to 77.87% in Q2 2023 from the same period last year, while for Mar 2024 it was 22.52%, marking a year-over-year change of. This contributed to the annual value of 32.15% for FY2023, which is N/A changed from last year.
  • Per Contineum Therapeutics' latest filing, its EBIT Margin stood at 77.87% for Q2 2023.
  • In the past 5 years, Contineum Therapeutics' EBIT Margin ranged from a high of 5559.78% in Q1 2023 and a low of 77.87% during Q2 2023